Statement re Sinclair Pharma plc announces appointment of Jean-Charles Tschudin as non-executive director

Sinclair Pharma plc announces appointment of Jean-Charles Tschudin as non-executive director 9 November 2007, Godalming, UK: Sinclair Pharma plc (LSE: SPH) is pleased to announce the appointment of Jean-Charles Tschudin as non-executive director, effective from 8 November 2007. Mr Tschudin has extensive experience in the pharmaceutical industry at a senior executive level. He was recently President and Chief Operating Officer of Yamanouchi Europe, the largest Japanese company in Europe (now Astellas). He has also held senior positions at Johnson & Johnson, Schering-Plough, Syntex and Cardinal Health. Mr Tschudin is currently non-executive director of SkyePharma PLC. No disclosures are required under section 9.6.13 of the Listing Rules. Andrew Sinclair, founder of Sinclair Pharmaceuticals Ltd in 1973 and currently a non-executive Director, will not seek re-election at the Company's Annual General Meeting. Mr Sinclair will maintain an advisory role with the company and will be appointed Honorary Life President. "We are very pleased that Jean-Charles Tschudin will be joining our Board," said Steve Harris, Chairman of Sinclair Pharma plc. "His considerable expertise will be invaluable as Sinclair continues its commercial development, particularly in the expansion of its European sales and marketing operations. We also thank Andrew Sinclair for his significant contribution to the company since the management buy-in in 2000, and we are delighted that he has agreed to maintain an advisory role with the company indefinitely." - ends - For further information please contact: Sinclair Pharma plc Tel: +44 (0) 1483 410 600 Dr Michael Flynn, CEO Jerry Randall, CFO Zoe McDougall, Director of Communications Capital MS&L Annabel O'Connor, Anna Mitchell Tel +44 (0)20 7307 5340 Notes to Editors: About Sinclair Pharma Plc www.sinclairpharma.com Sinclair Pharma plc is an international specialty pharmaceutical company. It has a growing sales and marketing operation that is already present in France, Italy, UK, Spain and Portugal, and a complementary marketing partner network that spans more than 80 countries. Sinclair has proven expertise in acquiring or developing commercially attractive and undervalued products, registering these products and bringing them to market within a short timeframe. The company focuses on niche therapeutic areas and its current portfolio includes products for dermatological conditions and oral health. "Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors. ---END OF MESSAGE---